Intelgenx Technologies (TSX:IGX) Growth Rank : 0 (As of Oct. 31, 2024)

View and export this data going back to 2008. Start your Free Trial

What is Intelgenx Technologies Growth Rank?

Intelgenx Technologies has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Intelgenx Technologies Growth Rank Related Terms

Thank you for viewing the detailed overview of Intelgenx Technologies's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Intelgenx Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intelgenx Technologies Corp (TSX:IGX) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

6420 Abrams, Ville Saint Laurent, QC, CAN, H4S 1Y2

Website

https://www.intelgenx.com

Intelgenx Technologies Corp is an oral drug delivery company. The company is focused on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilmTM technology platform. The company focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers a comprehensive portfolio of pharmaceutical services, including pharmaceutical R&D, clinical monitoring, regulatory support, tech transfer, and manufacturing scale-up, and commercial manufacturing. Its geographical segments are Europe, Canada, and the United States. The company generates the majority of its revenue from Europe.

Executives

Dana Matzen	Senior Officer
André Godin	Senior Officer
Tommy Kenny	Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
James Bernard Boudreau	Director
Ingrid Zerbe	10% Security Holder

Intelgenx Technologies Headlines

No Headlines